PL2188306T3 - Fragmenty powstałe po cięciu immunoglobuliny jako wskaźniki choroby oraz kompozycje do ich wykrywania i wiązania - Google Patents

Fragmenty powstałe po cięciu immunoglobuliny jako wskaźniki choroby oraz kompozycje do ich wykrywania i wiązania

Info

Publication number
PL2188306T3
PL2188306T3 PL08782610T PL08782610T PL2188306T3 PL 2188306 T3 PL2188306 T3 PL 2188306T3 PL 08782610 T PL08782610 T PL 08782610T PL 08782610 T PL08782610 T PL 08782610T PL 2188306 T3 PL2188306 T3 PL 2188306T3
Authority
PL
Poland
Prior art keywords
binding
compositions
detecting
cleavage fragments
disease indicators
Prior art date
Application number
PL08782610T
Other languages
English (en)
Inventor
Robert Jordan
Diane D. Petrone
Mary Ryan
Original Assignee
Janssen Biotech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech, Inc. filed Critical Janssen Biotech, Inc.
Publication of PL2188306T3 publication Critical patent/PL2188306T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
PL08782610T 2007-08-10 2008-08-04 Fragmenty powstałe po cięciu immunoglobuliny jako wskaźniki choroby oraz kompozycje do ich wykrywania i wiązania PL2188306T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95516207P 2007-08-10 2007-08-10

Publications (1)

Publication Number Publication Date
PL2188306T3 true PL2188306T3 (pl) 2017-01-31

Family

ID=40351057

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08782610T PL2188306T3 (pl) 2007-08-10 2008-08-04 Fragmenty powstałe po cięciu immunoglobuliny jako wskaźniki choroby oraz kompozycje do ich wykrywania i wiązania

Country Status (20)

Country Link
US (1) US20090155280A1 (pl)
EP (1) EP2188306B1 (pl)
JP (2) JP5530356B2 (pl)
KR (2) KR101588276B1 (pl)
CN (2) CN103497254B (pl)
AU (1) AU2008287128B2 (pl)
BR (1) BRPI0814355A2 (pl)
CA (1) CA2696011A1 (pl)
DK (1) DK2188306T3 (pl)
EA (1) EA025220B1 (pl)
ES (1) ES2593791T3 (pl)
HU (1) HUE029649T2 (pl)
IL (1) IL203544A (pl)
MX (1) MX2010001616A (pl)
NZ (1) NZ582916A (pl)
PL (1) PL2188306T3 (pl)
PT (1) PT2188306T (pl)
SG (1) SG183701A1 (pl)
WO (1) WO2009023457A1 (pl)
ZA (1) ZA201001689B (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501907B2 (en) * 2007-08-10 2013-08-06 Janssen Biotech, Inc. Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such
NZ623607A (en) 2009-10-23 2016-07-29 Millennium Pharm Inc Anti-gcc antibody molecules and related compositions and methods
AU2010318542B2 (en) 2009-10-29 2015-08-27 Janssen Biotech Inc. Antibody glycosylation variants
US8041225B2 (en) * 2009-12-21 2011-10-18 General Electric Company Contactless infrared data transmission for wind turbines
AU2010363981A1 (en) * 2010-11-19 2013-05-23 Janssen Biotech Inc. Immunoglobulin cleavage fragments vaccine compositions
DK2654780T3 (en) 2010-12-23 2017-04-10 Janssen Biotech Inc ACTIVE PROTEASE-RESISTANT ANTIBODY-FC MUTANTS
KR101820558B1 (ko) 2010-12-23 2018-02-28 유리타 아. 게. 넓은 영역에 나노 구조체를 생산하기 위한 시스템 및 방법
SG11201406855TA (en) * 2012-04-27 2014-11-27 Millennium Pharm Inc Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy
RU2714967C2 (ru) * 2013-12-27 2020-02-21 Чугаи Сейяку Кабусики Кайся Способ очистки антител с низкой изоэлектрической точкой
WO2015154052A1 (en) 2014-04-04 2015-10-08 Mayo Foundation For Medical Education And Research Isotyping immunoglobulins using accurate molecular mass
WO2017053932A1 (en) 2015-09-24 2017-03-30 Mayo Foundation For Medical Education And Research Identification of immunoglobulin free light chains by mass spectrometry
AU2017325022B2 (en) * 2016-09-07 2022-10-13 Mayo Foundation For Medical Education And Research Identification and monitoring of cleaved immunoglobulins by molecular mass
WO2019055634A1 (en) 2017-09-13 2019-03-21 Mayo Foundation For Medical Education And Research IDENTIFICATION AND MONITORING OF A MACROPHAGE APOPTOSIS INHIBITOR
TW201925233A (zh) * 2017-12-07 2019-07-01 日商中外製藥股份有限公司 抗體、用於在樣品中偵測或捕捉多肽的組成物以及在樣品中偵測或捕捉多肽的方法
US20210325380A1 (en) * 2020-04-20 2021-10-21 EnLiSense, LLC Disease diagnostics using a multi-configurable sensing array

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2162863T3 (es) * 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
AUPM322393A0 (en) * 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US7129331B2 (en) * 2000-05-31 2006-10-31 Pestka Biomedical Laboratories, Inc. Phosphorylated polypeptides and uses related thereto
GB0130228D0 (en) * 2001-12-18 2002-02-06 Hansa Medica Ab Protein

Also Published As

Publication number Publication date
KR20100059850A (ko) 2010-06-04
EP2188306B1 (en) 2016-06-29
ZA201001689B (en) 2011-06-29
US20090155280A1 (en) 2009-06-18
EP2188306A4 (en) 2011-03-02
WO2009023457A1 (en) 2009-02-19
CN103497254A (zh) 2014-01-08
ES2593791T3 (es) 2016-12-13
CN103497254B (zh) 2016-12-28
AU2008287128B2 (en) 2013-07-18
KR101588276B1 (ko) 2016-01-26
EA025220B1 (ru) 2016-12-30
NZ582916A (en) 2012-08-31
AU2008287128A1 (en) 2009-02-19
EA201070236A1 (ru) 2010-08-30
JP2014058535A (ja) 2014-04-03
IL203544A (en) 2015-07-30
KR20150059813A (ko) 2015-06-02
CN101889021A (zh) 2010-11-17
SG183701A1 (en) 2012-09-27
CA2696011A1 (en) 2009-02-19
BRPI0814355A2 (pt) 2015-01-27
JP5530356B2 (ja) 2014-06-25
HUE029649T2 (en) 2017-02-28
CN101889021B (zh) 2016-06-08
EP2188306A1 (en) 2010-05-26
JP2010536037A (ja) 2010-11-25
PT2188306T (pt) 2016-09-13
DK2188306T3 (en) 2016-08-22
MX2010001616A (es) 2010-03-15

Similar Documents

Publication Publication Date Title
ZA201001689B (en) Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such
HK1209631A1 (en) Modified macromolecule
EP2247310A4 (en) COMPOSITIONS AND METHODS FOR CRYSTALLIZING ANTIBODY FRAGMENTS
HK1177952A1 (en) Compositions for vaccinating against hsv-2 hsv-2
EP2089048A4 (en) COMPOSITION FOR CARTILAGE
GB2464430B8 (en) Emulsified composition
EP2021192A4 (en) IMPROVED SHEAR BAND
EP2185201A4 (en) COMPOSITIONS AND METHODS FOR CRYSTALLIZING ANTIBODIES
PL2061346T3 (pl) Kompozycja spożywcza zmniejszająca uczulenie na alergen
EP2148708A4 (en) COMPOSITION FOR PROMOTING BONE FORMATION
ZA201000983B (en) Methods and compositions for diagnosing disease
IL236237A (en) Tmem154 antibodies and their segments and uses
ZA200807960B (en) Catalyst composition
EP2068819A4 (en) Dendrimer COMPOSITIONS
ZA200903656B (en) Novel composition
GB0719065D0 (en) coalescing materials
EP2278984A4 (en) COMPOSITIONS AND METHODS FOR ENHANCING FERTILITY
EP1997013A4 (en) IDENTIFICATION OF MODIFICATIONS TO CONTENTS OF MEDIA DEVICES
GB0713232D0 (en) Staple remover
EP2034019A4 (en) COMPOSITION FOR THE NUCLEENIC ACID INTRODUCTION
GB0621329D0 (en) Novel composition
IL208188A0 (en) Compositions comprising antibodies or antibody fragments
PL386709A1 (pl) Kompozycja oczyszczająca
GB2450822B (en) Sample preparation
GB0621279D0 (en) Binding site